首页> 外文期刊>Journal of drug targeting >Cyclic RGDyK conjugation facilitates intracellular drug delivery of polymeric micelles to integrin-overexpressing tumor cells and neovasculature.
【24h】

Cyclic RGDyK conjugation facilitates intracellular drug delivery of polymeric micelles to integrin-overexpressing tumor cells and neovasculature.

机译:环状RGDyK偶联可促进聚合物微团的细胞内药物递送至过表达整联蛋白的肿瘤细胞和新脉管系统。

获取原文
获取原文并翻译 | 示例
           

摘要

On the basis of the fact of the overexpression of integrins in malignant tumor cells and neovasculature, and the advantage of polymeric micelles (PM) as the drug carriers, a cyclic RGD peptide (cRGDyK) was anchored on the surface of polyethylene glycol-b-poly(lactic-co-glycolic acid) (PEG-b-PLGA) micelles as a ligand of integrins in order to enhance the intracellular delivery of encapsulated hydrophobic drug into the tumor cells and its neovasculature. Toward this goal, PEG-b-PLGA micelles without or with cRGDyK conjugation loaded with paclitaxel (PTX) or DiI were prepared and characterized. The results revealed that drug-loaded micelles were stable in solution, with small diameters (<80 nm) and a low critical micelle concentration. Spectrophotofluorometry, confocal microscopy, and flow cytometry showed that cRGDyK-conjugated micelles (TPM) facilitated the cell-specific uptake of DiI into the murine melanoma B16-F10 cells and human umbilical vein endothelial cells (HUVEC) via integrin-mediated endocytosis compared with cRGDyK-free micelles (NPM), and the uptake was proportional to the ratio of cRGDyK modification in certain range. Meanwhile, PTX-loaded TPM displayed higher cytotoxicity and antiproliferation activities against both cells than PTX-loaded NPM. These results suggest that cRGDyK-coupled PEG-b-PLGA micelles may be the promising intracellular targeting carriers for efficient delivery of chemotherapeutic agents into tumor cells and neovasculature.
机译:基于在恶性肿瘤细胞和新脉管系统中整合素过表达的事实,以及高分子胶束(PM)作为药物载体的优势,环状RGD肽(cRGDyK)固定在聚乙二醇b聚(乳酸-乙醇酸)(PEG-b-PLGA)胶束作为整联蛋白的配体,以增强胶囊化疏水性药物向肿瘤细胞及其新脉管系统的细胞内递送。为了实现这一目标,制备并鉴定了不带有或不带有cRGDyK缀合物的PEG-b-PLGA胶束,并装有紫杉醇(PTX)或DiI。结果表明载药的胶束在溶液中稳定,直径小(<80 nm),临界胶束浓度低。分光光度法,共聚焦显微镜和流式细胞术表明,与cRGDyK相比,cRGDyK偶联的胶束(TPM)通过整合素介导的内吞作用促进了DiI对鼠黑色素瘤B16-F10细胞和人脐静脉内皮细胞(HUVEC)的细胞特异性摄取。胶束(NPM),其摄取与cRGDyK修饰比例在一定范围内成正比。同时,载有PTX的TPM比载有PTX的NPM表现出更高的针对两种细胞的细胞毒性和抗增殖活性。这些结果表明,cRGDyK偶联的PEG-b-PLGA胶束可能是有前途的细胞内靶向载体,可将化疗药物有效地递送到肿瘤细胞和新脉管系统中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号